Scholar Rock Holding Corporation
SRRK
Peringkat dalam Saham
#3423
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Harga Saham
$41.58
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$5.06B
Perubahan (1 hari)
3.34%
Perubahan (1 tahun)
47.62%
Negara
US
Perdagangan Scholar Rock Holding Corporation (SRRK)
Kategori
Healthcare
Rasio P/E untuk Scholar Rock Holding Corporation (SRRK)
Rasio P/E per October 2026 TTM: -11.96
Menurut laporan keuangan dan harga saham terbaru dari Scholar Rock Holding Corporation, rasio P/E saat ini (TTM) adalah -11.96. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -8.62.
Riwayat rasio P/E untuk Scholar Rock Holding Corporation dari 2016 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -11.96 | -31.71% |
| 2024 | -17.52 | 103.34% |
| 2023 | -8.62 | 110.25% |
| 2022 | -4.10 | -40.77% |
| 2021 | -6.92 | -60.57% |
| 2020 | -17.55 | 140.29% |
| 2019 | -7.30 | 0.18% |
| 2018 | -7.29 | -34.34% |
| 2017 | -11.10 | -35.16% |
| 2016 | -17.12 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -340.58% |
US
|
|
| -28.36 | 137.04% |
US
|
|
| -24.57 | 105.35% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -353.52% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.